The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.

@article{Gane2010TheMA,
  title={The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.},
  author={Edward J. Gane and Frank Weilert and David W. Orr and Geraldine F Keogh and Michael Gibson and Michelle Marie Lockhart and Christopher Miles Frampton and K. M. Taylor and Robin A. J. Smith and Michael P Murphy},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2010},
  volume={30 7},
  pages={1019-26}
}
BACKGROUND Increased oxidative stress and subsequent mitochondrial damage are important pathways for liver damage in chronic hepatitis C virus (HCV) infection; consequently, therapies that decrease mitochondrial oxidative damage may improve outcome. The mitochondria-targeted anti-oxidant mitoquinone combines a potent anti-oxidant with a lipophilic cation that causes it to accumulate several-hundred fold within mitochondria in vivo. AIMS In this phase II study, we investigated the effect of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS